2179.HK

Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully

Retrieved on: 
星期四, 四月 7, 2022
People, Shingles, Innovation, HFMD, Investment, III, HPV, Protein engineering, Board, Adult, Vaccine, Research, General manager, Investor, Philosophy, WuXi Biologics, Industry, Technology, RNA transfection, Cervical cancer, COVID-19, Wuxi, COVID-19 vaccine, Tuberculosis, R, Founder, Patient, Hong Kong Stock Exchange, Property management

HONG KONG, Apr 7, 2022 - (ACN Newswire) - On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange.

Key Points: 
  • HONG KONG, Apr 7, 2022 - (ACN Newswire) - On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange.
  • Recbio is a novel vaccine company driven by independent novel adjuvant technology.
  • As the major institutional investor to Recbio, Legend Capital provides Recbio with multi-faceted support involving corporate governance, business strategy, technical route, R&D resources, management improvement and financial support.
  • Hank Zhou, the Co-Chief Investment Officer of Legend Capital, said: "Congratulations to Recbio and its team led by founder Dr. Liu Yong.

Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology

Retrieved on: 
星期五, 四月 1, 2022
Company, Cornerstone, CAGR, Benchmarking, Shingles, HFMD, World Health Organization, Protein engineering, III, HPV, Transport, Public health, Board, Adult, Vaccine, EUA, Temasek, Yangtze River Pharmaceutical Group, Research, Delta, Environment, Cervical cancer, World, General manager, GFA, Frost & Sullivan, Global, Omicron, Technology, Safety, TB, RNA transfection, Depression, COVID-19, Intellectual property, Pharmaceutical industry, Frost, COVID-19 vaccine, Tuberculosis, GMP, IPO, FDA, Development, Founder, R, Temperature, Hong Kong Stock Exchange, Recovered-memory therapy

Regarding the development of the vaccine industry, the "Plan" also states that research and development of novel vaccines (such as novel adjuvants for vaccines and mRNA vaccines) and building of industrialization capability shall be accelerated.

Key Points: 
  • Regarding the development of the vaccine industry, the "Plan" also states that research and development of novel vaccines (such as novel adjuvants for vaccines and mRNA vaccines) and building of industrialization capability shall be accelerated.
  • Currently, Recbio has formed a full coverage of bivalent, quadrivalent and 9-valent vaccines and novel adjuvant upgrades in the field of HPV vaccines.
  • The novel adjuvant which benchmarking AS01 is adopted in REC610 of the Company, significantly improving vaccine immunogenicity, hoping to achieve domestic substitution quickly.
  • Founded in 2012, Recbio is an innovative vaccine company with independent research and development technology as its core driving force.

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
星期日, 三月 20, 2022
BLA, CAGR, HFMD, Adult, Vaccine, EUA, HK, NMPA, Healthcare industry, Technology, TB, Stock exchange, Pi, Solution, GMP, Science, Frost, Disease, Hong Kong Stock Exchange, Post-exposure prophylaxis, Sequoia Capital, Population, Cros, Investor, GFA, Global, Industry, Development, Shingles, WHO, III, Clinical trial, Growth, Motherboard, Core product, Board, Temasek, IPD, S. D. Warren Co. v. Maine Board of Environmental Protection, Data analysis, IND Queens Boulevard Line, Cervical cancer, COVID-19 vaccine, FDA, Recovered-memory therapy, Company, HPV, Compliance, AS04, Research, Antigen, General manager, Frost & Sullivan, Safety, Disability-adjusted life year, COVID-19, CLSA, R, Tuberculosis, Property management, Pharmaceutical industry

Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday).

Key Points: 
  • Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday).
  • Dealings in H Shares of Recbio on the Main Board of the Hong Kong Stock Exchange is expected to commence on 31 March 2022 (Thursday).
  • -- China Industrial Securities International Capital Limited, Haitong International Securities Company Limited, GF Securities (Hong Kong) Brokerage Limited, Essence International Securities (Hong Kong) Limited and Valuable Capital Limited (in relation to the Hong Kong Public Offering only) are the Joint Bookrunners and Joint Lead Managers.
  • Recbio is the vaccine company with a high-value vaccine portfolio driven by in-house developed technologies.